Table 4.
NELCN tumour tissue BRCA1/BRCA2 next generation sequencing analysis.
| Category | Successfully Reported (n,%) | Failed Analysis (n,%) |
|---|---|---|
| Total number of samples | 213/232 (91.8%) | 19/232 (8.9%) * |
| Type of tissue | ||
| Pre-chemo diagnostic biopsy | 37/48 (77.1%) | 11/48 (22.9%) |
| Primary surgery | 104/110 (94.5%) | 6/110 (5.5%) |
| Post-chemo cytoreductive surgery | 72/74 (97.3%) | 2/74 (2.7%) |
| Type of tumour sample | ||
| 3 mm core from FFPE | 171/174 (98.3%) | 3/174 (1.7%) |
| 5 × 5µM unstained slides | 42/58 (72.4%) | 16/58 (27.6%) |
| Neoplastic content | ||
| <20% | 5/11 (45.5%) | 6/11 (54.5%) |
| 20–50% | 33/40 (82.5%) | 7/40 (17.5%) |
| >50% | 175/181 (96.7%) | 6/181 (3.4%) |
This table describes the results of BRCA testing of tumour tissue in the NELCN cohort. Results are available for 232 cases. * Of the 19 failed analysis, one had a BRCA1 PV and one a RAD51D PV.